NEW YORK (Reuters Health) – Anticoagulants may help reduce the risk of stroke, according to the latest medical research. The researchers at the University of Nottingham in Britain found that the administration of tranexamic acid (TXA) for people with cerebral hemorrhage reduced the number of deaths in the first and subsequent days of stroke. The amount of bleeding in the brain and the number of serious complications associated with Patients treated with tranixamic acid (TXA). However, the experiment did not find any difference in the number of people who left disabled or died three months after stroke, and researchers believe that more study is needed on larger groups of patients to enable them to fully understand the potential benefits. “Tranexamic acid is cheap and widely available, so it has the potential to reduce deaths and disability worldwide,” said Nikola Sprigg, who led the experiment. The study showed that 15% of strokes – affecting about 22,000 people a year – are due to haemorrhagic stroke when the blood vessels in the brain explode, resulting in permanent damage. While all people with acute stroke benefit from treatment Stroke unit, there is currently no specific treatment for haemorrhagic stroke, exposing many people affected to death within a few days, often leaving those who survive with debilitating disabilities including paralysis and inability to speak. The study, which lasted from 2013 to 2017, was conducted on more than 2,000 patients from 124 hospitals in 12 countries, randomly assigned to two groups of patients. The first group received transaxic acid (TXA) while the second group took placebo . In the United Kingdom, more than 80 hospitals participated in the study, supported by the Clinical Research Network of the National Institute for Human Rights. CT scans were performed 24 hours after a stroke. Their progress was monitored and measured on day 2, Stroke. The final follow-up will be carried out in 90 days. The study found that the death among the tranicacamic group was lower, and fewer of them suffered from a worsening of brain hemorrhage, compared to their counterparts in the placebo group.